We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Centene (CNC) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Centene (CNC - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Centene is one of 916 individual stocks in the Medical sector. Collectively, these companies sit at #10 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Centene is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for CNC's full-year earnings has moved 42.2% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, CNC has moved about 57.9% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 2.3% on a year-to-date basis. As we can see, Centene is performing better than its sector in the calendar year.
Another Medical stock, which has outperformed the sector so far this year, is Alzamend Neuro, Inc. (ALZN - Free Report) . The stock has returned 6.6% year-to-date.
Over the past three months, Alzamend Neuro, Inc.'s consensus EPS estimate for the current year has increased 59.6%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Centene belongs to the Medical - HMOs industry, a group that includes 7 individual stocks and currently sits at #32 in the Zacks Industry Rank. On average, this group has gained an average of 16.3% so far this year, meaning that CNC is performing better in terms of year-to-date returns.
On the other hand, Alzamend Neuro, Inc. belongs to the Medical - Biomedical and Genetics industry. This 437-stock industry is currently ranked #165. The industry has moved +7% year to date.
Centene and Alzamend Neuro, Inc. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
View the Zacks #1 Rank List
Image: Bigstock
Is Centene (CNC) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Centene (CNC - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Centene is one of 916 individual stocks in the Medical sector. Collectively, these companies sit at #10 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Centene is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for CNC's full-year earnings has moved 42.2% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, CNC has moved about 57.9% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 2.3% on a year-to-date basis. As we can see, Centene is performing better than its sector in the calendar year.
Another Medical stock, which has outperformed the sector so far this year, is Alzamend Neuro, Inc. (ALZN - Free Report) . The stock has returned 6.6% year-to-date.
Over the past three months, Alzamend Neuro, Inc.'s consensus EPS estimate for the current year has increased 59.6%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Centene belongs to the Medical - HMOs industry, a group that includes 7 individual stocks and currently sits at #32 in the Zacks Industry Rank. On average, this group has gained an average of 16.3% so far this year, meaning that CNC is performing better in terms of year-to-date returns.
On the other hand, Alzamend Neuro, Inc. belongs to the Medical - Biomedical and Genetics industry. This 437-stock industry is currently ranked #165. The industry has moved +7% year to date.
Centene and Alzamend Neuro, Inc. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.